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SUMMARY Atopic dermatitis (AD) is an inflammatory skin disease 
characterized by chronic and recurrent course, beginning primarily in 
early childhood. The etiopathogenesis of AD has not yet been fully 
understood, although various types of inflammatory cells including 
eosinophils may be involved in its pathomechanism. The basic aim 
of the study was to evaluate the usefulness of selected eosinophil 
proteins in serum and urine of AD patients, as markers of disease 
severity. The study also aimed to analyze correlations between the 
level of examined proteins and parameters such as skin prick test 
(SPT) results, serum concentration of total IgE, and coexistence of 
symptoms of other atopic diseases. The study included 30 AD patients 
and two control groups: 30 patients suffering from chronic urticaria 
and 30 healthy individuals. The mean level of eosinophil proteins 
measured in serum and urine of AD patients was higher than that 
in controls, although a significant difference was only recorded for 
serum and urine level of eosinophil protein X (EPX). Patients with very 
severe/severe AD presented higher levels of eosinophil proteins than 
patients presenting with mild/moderate AD, although no significant 
difference was found between these two groups. AD patients with 
positive SPT results and detectable specific IgE in serum, and with 
coexisting symptoms of other atopic diseases presented with higher 
mean levels of serum and urine eosinophil proteins than AD cases 
with negative SPT results and without any symptoms of other atopic 
diseases. In children suffering from AD, serum eosinophil cationic 
protein level, EPX level and urine EPX level were higher than those in 
healthy children, however, without statistical significance. Study results 
suggested a significant role of eosinophils in the etiopathogenesis of 
AD. Serum and urine levels of selected eosinophil proteins may serve 
as an important part of diagnostic approach to AD patients, especially 
in differentiation of allergic and non-allergic forms of AD. The results 
are also promising for the usefulness of selected eosinophil proteins in 
the diagnosis of AD in children, however, thorough analysis on a larger 
group of patients is needed.
KEY WORDS: atopic dermatitis; eosinophil proteins; airborne 
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INTRODUCTION
 Atopic dermatitis (AD) is an inflammatory, high-
ly pruritic skin disorder, characterized by chronic 
and recurrent course, and onset usually in early 
childhood. The etiopathogenesis of AD still re-
mains unclear, although various immune dysfunc-
tions are observed, e.g., elevated serum level of 
74
Jenerowicz et al.     Acta Dermatovenerol Croat
Selected eosinophil proteins in atopic dermatitis                 2006;14(2):73-80 
total IgE (tIgE) antibodies, enhanced production 
and release of Th2 cytokines in acute phase of AD, 
and also disturbed function of keratinocytes as a 
protective barrier (1,2). Many inflammatory cell 
types are actively involved in the pathogenesis of 
AD, including eosinophils. Increased expansion, 
activation and tissue recruitment, together with de-
layed apoptosis of these cells can be observed in 
AD. Proinflammatory cytokines and chemokines 
(RANTES, eotaxin, IL-5, IL-13) produced by an-
tigen presenting cells and T lymphocytes attract 
eosinophils to the area of inflammation and acti-
vate them. Studies show that eosinophils disrupt in 
tissues and lose their morphological identity, and 
release numerous mediators, localized initially in 
specific cytoplasmic granules. Among them, eosin-
ophil cationic protein (ECP) and eosinophil derived 
neurotoxin/eosinophil protein X (EDN/EPX) are 
considered as essential markers of eosinophilic 
activity (2-4). Biologically active concentrations of 
eosinophil proteins persist in the skin for weeks 
and they likely play an important role in the inflam-
matory process, even if intact eosinophil granulo-
cytes are not present.  
 The most important functions of ECP are as-
sociated with its strong cytotoxic features. ECP 
demonstrates highly destructive action against 
bacteria, parasites and some mammalian cells. 
Increased eosinophilic activity, expressed by ECP 
body fluid level, can be found in numerous dis-
eases, although special attention is drawn to the 
involvement of this protein in atopic inflammation, 
particularly in AD (5-8).
 EPX shares many features with ECP. Studies 
have indicated that these proteins show an almost 
70% homology regarding amino acid configuration. 
In contrast to ECP, however, EPX is excreted in 
significant amounts in the urine. Increased serum/
urine level of this protein was detected in patients 
with asthma, prurigo nodularis and also in patients 
suffering from AD (5-8).
 The aim of the present study was to investigate 
the usefulness of selected eosinophil proteins de-
tected in blood serum and urine of AD patients as 
markers of disease severity, evaluation of correla-
tion between serum and urine level of analyzed 
proteins, and certain clinical and allergologic pa-
rameters, e.g, skin prick test (SPT) results, levels 
of IgE antibodies directed against environmental 
allergens, and coexistence of other atopic dis-
eases symptoms (asthma, allergic rhinitis). We 
also aimed to analyze the above correlations in a 
group of children suffering from AD and to evalu-
ate EPX urine level in AD children as an essential 
and noninvasive diagnostic tool in this age group. 
 SUBJECTS AND METHODS
Subjects
 Thirty patients suffering from AD diagnosed 
by use of Hanifin and Rajka criteria (9) were in-
cluded in the study. There were 22 (73%) female 
and 8 (27%) male patients, age range 8-60 (mean 
24.5) years, including 11 children (7 female and 
4 male) with upper age limit of 17 years, mean 
age 12 years. All patients were hospitalized at 
Department of Dermatology or attended Allergic 
Diseases Diagnostic Center, University of Medical 
Sciences in Poznań. 
 In addition to AD symptoms, 15 (50%) patients 
presented with other atopic disease manifesta-
tions: atopic asthma in 4 (13.3%), allergic rhini-
tis in 11 (36.7%) and allergic conjunctivitis in 12 
(40%) patients.
 Two age- and sex-matched control groups were 
included in the study: control group A (30 patients 
suffering from chronic urticaria) and control group 
B (30 healthy individuals).
Methods
 Thorough disease history was taken regarding 
the onset and course of AD, factors exacerbat-
ing the inflammatory state of the skin, perennial 
disease activity, concomitant symptoms of other 
atopic diseases, and family history of atopy. 
 Clinical evaluation of AD patients was based on 
W-AZS index proposed by Silny et al. (10), which 
grades the severity of pruritus, sleep disturbances 
together with extensiveness and severity of skin 
inflammation. The principles of W-AZS have been 
recently published by Czarnecka-Operacz et al. 
(11), and consecutive study of the usefulness and 
advantages of W-AZS index in the appraisal of 
a patient with AD has already been accepted for 
publication in Acta Dermatovenerologica Croatica. 
In the group of chronic urticaria patients, both skin 
lesions and severity of pruritus were evaluated us-
ing the scores proposed by Lorette et al. (12) and 
Thomson et al. (13).
 SPTs were performed in 30 AD patients and 
control group B using airborne set of allergens by 
Nexter/Allergopharma (grass pollen, tree pollen, 
weed pollen, feather, animal dander, moulds and 
house dust mites Dermatophagoides (D.) pteron-
yssinus and Dermatophagoides (D.) farinae). In 
control group A (chronic urticaria patients), SPTs 
were only performed if the history suggested the 
possibility of airborne allergen contribution to the 
pathogenesis of the disease and in patients pre-
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senting additional symptoms indicating airborne 
allergy. Histamine hydrochloride (1:1000) was 
used as positive control, and 0.9% saline solution 
as negative control. Positive SPT result (+++) was 
defined as an allergen wheal with a mean diam-
eter at least equal to the mean diameter of his-
tamine wheal (14). Laboratory analyses included 
measurement of total IgE (tIgE) serum level using 
fluoroenzyme immunoassay (CAP System FEIA, 
Pharmacia); measurement of antigen specific 
IgE (asIgE) serum level using fluoroenzyme im-
munoassay (CAP System FEIA, Pharmacia); the 
measurement was only performed in selected AD 
cases where disease severity excluded the patient 
from SPT; evaluation of ECP serum level using 
fluoroenzyme immunoassay (CAP System FEIA, 
Pharmacia); analysis of EPX serum and urine lev-
el using EDN ELISA method (MBL Intl., USA): ac-
cording to literature data on the circadian rhythm 
of EPX excretion, urine was collected in the morn-
ing and then centrifuged and frozen (-70 ºC). In or-
der to formulate uEPX concentration as μg/mmol 
creatinine, measurement of creatinine urine level 
was performed using Jaffe’s method (15).
 The study was approved by the Ethics Com-
mittee of the University of Medical Sciences in 
Poznań (statement number 502/03).
STATISTICAL METHODS
 Statistical evaluations were performed by using 
ANOVA analysis with post-hoc tests by Newmann-
Keuls. For the evaluation of correlations, Spear-
man’s rank correlation coefficient was calculated 
for statistical significance. Statistical analysis was 
carried out with STATISTICA v. 6.0 and Instat v. 
3.0 by GrafPad.
RESULTS
 Based on the clinical evaluation of AD patients 
two subgroups were established: subgroup I of 17 
AD patients, W-AZS value <50 points (mild and 
moderate AD) and subgroup II of 13 AD patients, 
W-AZS value ≥points (severe and very severe AD). 
SPT results were positive in 80.8% and negative 
in 19.2% of AD patients. The sensitizing airborne 
allergens were predominated by house dust mites 
and grass pollen allergens; 72% of study patients 
presented sensitization to numerous groups of al-
lergens (polyvalent allergy), while 28% of patients 
were sensitized to only one group of allergens 
(monovalent allergy). In control group B (healthy 
individuals) SPT results were positive in 26.7% 
and negative in 73.3% of subjects. The majority of 
healthy subjects presented sensitization to grass 
pollen allergens; 25% of healthy individuals sensi-
tized to airborne allergens presented sensitization 
to numerous groups of allergens (polyvalent al-
lergy) and 75% were sensitized to only one group 
of allergens (monovalent allergy).
 The mean serum ECP level in AD patients was 
8.9±9.6 μg/L and was higher than that in control 
groups A and B (5.2±4.4 μg/L and 5.7±6.6 μg/L, 
respectively). The difference between groups did 
not reach statistical significance. The mean serum 
EPX level in AD patients was 44.4±40.9 ng/mL 
and also exceeded the serum level of this mark-
er recorded in control groups (23±12.2 ng/mL in 
control group A and 20.2±14.5 ng/mL in control 
group B). Statistical analysis yielded a statisti-
cally significant difference between AD patients 
and control group A (p<0.05) and control group B 
(p<0.001). Similar results were obtained in rela-
tion to the mean urine EPX level: in the group of 
AD patients it was higher (118.4±62.9 μg/mmol 
creatinine) than that in control groups A and B 
(83.7±50.7 μg/mmol creatinine and 65±24.5 μg/
mmol creatinine, respectively). There was a statis-
tically significant difference between AD patients 
and control group A (p<0.01) and control group B 








Mean serum ECP level
(μg/L) ±SD
8.9±9.6a 5.2±4.4b 5.7±6.6c a/b NSa/c NS 
b/c NS
Mean serum EPX level
(ng/mL) ±SD
44.3±40.9a 23.7±12.2b 20.2±14.5c a/b p<0.05a/c p<0.001
b/c NS
Mean urine EPX level (μg/mmol 
creatinine)
±SD
118.4±62.9a 83.7±50.7b 65.5±24.5c a/b p<0.01a/c p<0.001
b/c NS
Table 1. Results of eosinophil protein measurements in AD patients and control groups
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 In the group of AD patients serum and urine 
EPX levels correlated significantly with tIgE se-
rum level. There was no statistically significant 
correlation between ECP and tIgE serum level. 
 The results of the eosinophil protein urine 
level measurement in patients with AD catego-
rized into two subgroups according to disease 
severity (W-AZS index) were evaluated. In sub-
group I of AD patients (mild and moderate AD) 
the mean serum ECP level was 8.3±7.9 μg/L and 
was slightly lower than that in subgroup II (severe 
and very severe AD) (9.9±11.7 μg/L). There was 
no statistically significant difference between the 
two groups. Similarly, the mean serum and urine 
EPX level (Fig. 1) was analyzed in the two sub-
groups of AD patients, and was found to be lower 
in subgroup I than in subgroup II (43.9±42.6 ng/
mL and 106.7±64.3 μg/mmol creatinine in sub-
group I; and 44.8±40.2 ng/mL and 133.6±60.0 μg/
mmol creatinine in subgroup II). Statistical analy-
sis showed no difference between these groups. 
 The mean serum ECP level in AD patients pre-
senting symptoms of other atopic diseases was 
12.0±12.4 μg/L and exceeded the level of this 
marker in AD patients with no symptoms of other 
atopic diseases (5.9±3.7 μg/L), although there 
was no statistically significant difference between 
the groups. The mean serum EPX level in AD pa-
tients with other atopic diseases was higher than 
that in the group presenting no signs of additional 
atopic diseases (59.7±53.1 ng/mL and 28±11.8 
ng/mL, respectively), however, with no statisti-
cally significant between group difference. Simi-
larly, the mean urine level of EPX in AD patients 
showing symptoms of other atopic diseases was 
higher than that in the group free from additional 
symptoms of atopic diseases, however, without 
statistically significant between group difference 
(122.6±70.7 μg/mmol creatinine and 114.1±56.1 
μg/mmol creatinine, respectively).
 Further analysis referred to the level of eosino-
phil proteins in serum and urine of AD patients de-
pending on SPT results. In AD patients with posi-
tive SPT results and detectable serum asIgE, the 
mean serum level of ECP was higher than that in 
patients with negative SPT results, although the 
difference was not statistically significant (9.7±10.0 
μg/L and 5.2±5.8 μg/L, respectively). As shown in 
Table 2, the mean serum and urine EPX level in 
AD patients presenting with positive SPT results 
and detectable serum asIgE was 49.5±42.9 ng/
mL and 125.8±64.8 μg/mmol creatinine, respec-
tively, exceeding the serum and urine level of this 
marker in AD patients with negative SPT results 
(18.4±9.1 ng/mL; statistically significant differ-
ence, p<0.05, and 81.3±37.7 μg/mmol creatinine, 
no statistically significant difference, respectively). Figure 1. Mean urine EPX level in AD patients 





Patients with positive SPT 
results and detectable 
serum asIgE
n=25
Patients with negative SPT 
results
n=5
Mean serum ECP level
(μg/L) ±SD 9.7±10.0
a 5.2±5.8b a/b NS
Mean serum EPX level
(ng/mL) ±SD 49.5±42.9
a 18.4±9.1b a/b p<0.05
Mean urine EPX level (μg/mmol 
creatinine) ±SD 125.8±64.8
a 81.3±37.7b a/b NS
Table 2. Comparison of eosinophil protein levels in AD patients presenting with positive SPT results and 
detectable serum asIgE and patients with negative SPT results according to selected airborne allergens
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Figure 1. Mean urine EPX level in AD patients categorized into two subgroups according to 
disease severity. 
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 Evaluation of special interest considered se-
rum and urine level of eosinophil proteins in the 
group of children suffering from AD in comparison 
to healthy subjects. The mean serum ECP level 
was 9.0±9.7 μg/L in AD children and slightly lower 
in healthy children (8.3±12.5 μg/L), with no statisti-
cally significant difference. The mean serum EPX 
level in AD children was 46.5±52.5 ng/mL, which 
was higher than the level measured in healthy chil-
dren (28.2±27.2 ng/mL), however, with no statisti-
cally significant difference. The mean level of EPX 
measured in urine of AD children was 112.2±89.4 
μg/mmol creatinine, which was higher than that 
recorded in healthy children (69.7±16.8 μg/mmol 
creatinine). There was no significant difference 
between the two groups. These results are shown 
in Table 3.
DISCUSSION
 Active participation of eosinophil proteins in the 
etiopathogenesis of AD and their value as mark-
ers of disease activity in both adults and children 
have been the subject of broad investigations per-
formed by several researchers all over the world. 
ECP has been evaluated as a sensitive measure 
by several authors. Kägi et al. (16), Miyasato et al. 
(17) and Tsuda et al. (18) found significantly higher 
serum levels of ECP in AD patients as compared 
with control groups. Moreover, according to Tsuda 
et al. (18), serum ECP level significantly correlates 
with the quantity of «hypodense» eosinophils in 
peripheral blood, suggesting that elevated serum 
ECP level may be the consequence of degranula-
tion of circulating activated eosinophils. Amon et 
al. (19) showed a statistically significant correla-
tion between serum ECP level and actual clinical 
status measured using SCORAD index in a large 
population of randomly selected AD patients. How-
ever, the authors did not observe any pronounced 
increase in ECP with increasing disease sever-
ity, and therefore conclude that determination of 
serum ECP levels on admission and at discharge 
may not be a valid tool for routine evaluation in 
unselected AD patients. In the present study, the 
mean serum ECP level was higher in the group of 
30 AD patients in comparison to control groups, 
although the difference was not statistically signifi-
cant. Furthermore, serum ECP level was slightly 
higher in patients with severe and very severe dis-
ease than in those with mild and moderate AD, 
with no significant between group difference. We 
found no statistically significant correlation be-
tween W-AZS index value and serum ECP level. 
 In patients presenting allergic type of AD (posi-
tive SPT results, detectable serum asIgE), the 
mean serum level of ECP was distinctly higher 
than in patients presenting non-allergic type of 
AD (negative SPT results, serum asIgE not de-
tectable). These results are consistent with litera-
ture data. According to Toma et al. (20), in severe 
cases of AD circulating eosinophils are activated 
to express CD69 antigens on the surface after in 
vivo challenge with airborne allergens. Moreover, 
Kägi et al. (16) measured peripheral eosinophilia, 
serum ECP and sIL-2R level in AD patients. There 
was no statistically significant difference between 
patients presenting allergic and non-allergic type 
of AD, although serum ECP level was higher in 
patients with allergic AD. 
 ECP shares several features with EPX, howev-
er, a unique characteristic of EPX is that apart from 
its presence in human serum it is also excreted 
in urine. Therefore, as a laboratory parameter for 
monitoring inflammation in AD, EPX seems to be 
potentially more suitable and practical than ECP, 
mainly because there is no need to use complex 
and time consuming procedures of blood collect-
ing and storage.
 In 1994 Ott et al. (21) found the serum and 
urine concentration of EPX to be elevated in pa-
tients suffering from AD in comparison to healthy 
individuals, although the authors failed to demon-






Mean serum ECP level
(μg/L) ±SD
9.0±9.7a 8.3±12.5b a/b NS
Mean serum EPX level
(ng/mL) ±SD
46.5±52.5a 28.2±27.2b a/b NS
Mean urine EPX level (μg/mmol 
creatinine) ±SD
112.2±89.4a 69.7±16.8b a/b NS
Table 3. Results of eosinophil protein measurements in serum and urine of children suffering from AD 
and in healthy individuals
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parameters and the patients’ clinical state. Breuer 
et al. (22) examined 40 adult AD patients and 
acknowledged urine EPX as a valuable marker 
of disease activity. Urine level of EPX correlated 
significantly with disease activity as assessed by 
SCORAD index.
 In the present study the mean serum and urine 
EPX level was significantly higher in AD patients 
than in control groups. Moreover, in the group of 
patients with severe and very severe AD, serum 
and urine EPX exceeded the level of this marker 
recorded in patients with mild to moderate AD, how-
ever, with no statistical significance. There was no 
statistically significant correlation between serum 
and urine EPX level and W-AZS index value.
 Serum and urine EPX level was higher in pa-
tients presenting allergic type of AD than in those 
with non-allergic type of AD; in case of serum EPX 
level there was a statistically significant between 
group difference. Therefore, EPX measured in se-
rum and urine may serve as a useful parameter 
in differentiating allergic and non-allergic types of 
AD. These results are consistent with the obser-
vations made by Oymar et al. (23), who proved a 
significant difference in urine EPX level between 
patients sensitized to common environmental al-
lergens and those with no sensitization. Accord-
ing to the authors, urine EPX level distinguishes 
the two groups of patients better than serum ECP 
level.
 In our study, AD patients presenting symptoms 
of other atopic diseases had higher levels of se-
rum and urine EPX than AD patients with no other 
atopic diseases. There was no statistically signifi-
cant difference between the groups, and studies in 
a larger group of patients are needed to reach it.
 Several authors assessed the value of eosino-
phil proteins in children suffering from AD. Par-
ticularly EPX seems to be a promising parameter 
in this age group, for its detection is noninvasive, 
painless and easy.
 Pucci et al. (24,25) proved the serum and urine 
EPX level to be significantly higher in AD children 
than in healthy subjects. Moreover, the authors 
demonstrated a significant correlation between 
urine EPX level and subjective symptoms such as 
skin pruritus and sleep disturbances, suggesting 
the possible role of eosinophil proteins in the etio-
pathogenesis of pruritus. In the study evaluating 
infants and young children with AD, the authors 
also found a strong positive correlation between 
immune parameters (serum ECP and urine EPX 
level) and each of the SCORAD index items, which 
they consider as the gold standard for assessing 
disease severity in clinical trials. According to oth-
er researchers (23), EPX measured in serum and 
urine taken together can give more information on 
the disease severity and may also be a helpful pa-
rameter in differentiation of AD children presenting 
allergic and non-allergic type of the disease. On 
the other hand, Selnes and Dotterud (26) found 
no association between serum ECP and AD or 
allergic rhinitis in children aged 7-12 years. The 
authors emphasize that the study was performed 
in an unselected children population; however, 
in order to evaluate the usefulness of eosinophil 
proteins, measurements in community medicine 
and trials in unselected populations are essential. 
Neither could Wolkerstorfer et al. (27) confirm a 
significant relationship between serum ECP level 
and clinical activity in children suffering from mild 
to moderate AD. In the authors’ opinion, the lack 
of correlation between ∆SCORAD and ∆ECP may 
indicate a distinct ongoing eosinophil activity, even 
if the clinical status has clearly improved. Accord-
ing to our investigations, serum levels of ECP and 
EPX as well as urine level of EPX were higher in 
the children suffering from AD than in healthy indi-
viduals, however, we failed to obtain a statistically 
significant difference between these groups. Yet, 
there is a possibility that increasing the number of 
study children will allow us to perform a more de-
tailed analysis of the expected relationship, there-
fore we consider the results obtained as a promis-
ing encouragement for further investigations.
CONCLUSIONS
 Determination of serum and urine levels of 
selected eosinophil proteins in AD patients may 
serve as an important supplementary component 
in the evaluation of the course of the disease.
 In AD patients presenting allergic type of the 
disease the serum and urine level of eosinophil 
proteins was higher than that in patients present-
ing non-allergic type of AD; thus, it may be consid-
ered as a helpful marker in differentiating the two 
types of AD.
 Determination of urine EPX level appears to 
be especially valuable in the diagnosis of AD chil-
dren, considering its noninvasiveness and simple 
performance.
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